Sign in →

Test Code GBETH General Factor Bethesda Units, Plasma


Ordering Guidance


If type of inhibitor is unknown, see APROL / Prolonged Clot Time Profile, Plasma.



Specimen Required


Only orderable as a reflex. For more information see:

-ALBLD / Bleeding Diathesis Profile, Limited, Plasma

-APROL / Prolonged Clot Time Profile, Plasma

-2INHE / Factor II Inhibitor Evaluation, Plasma

-7INHE / Factor VII Inhibitor Evaluation, Plasma

-10INE / Factor X Inhibitor Evaluation, Plasma

-11INE / Factor XI Inhibitor Evaluation, Plasma


Useful For

Detecting and quantifying the presence and titer of a specific factor inhibitor directed against a specific coagulation factor

Method Name

Only orderable as a reflex. For more information see:

-ALBLD / Bleeding Diathesis Profile, Limited, Plasma

-ACBL / Bleeding Diathesis Profile, Comprehensive, Plasma

-APROL / Prolonged Clot Time Profile, Plasma

-2INHE / Factor II Inhibitor Evaluation, Plasma

-7INHE / Factor VII Inhibitor Evaluation, Plasma

-10INE / Factor X Inhibitor Evaluation, Plasma

-11INE / Factor XI Inhibitor Evaluation, Plasma

 

Optical Clot-Based

Reporting Name

General Factor Bethesda Units, P

Specimen Type

Plasma Na Cit

Specimen Stability Information

Specimen Type Temperature Time Special Container
Plasma Na Cit Frozen 14 days

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject

Clinical Information

Significant bleeding can result from the presence of a coagulation factor inhibitor and could be life threatening. Whether the inhibitor is present due to hemophilia or is of an acquired nature, it greatly complicates the treatment process of a decreased factor level. The titer of the inhibitor may determine the mode of treatment. Bethesda units are a standardization to give a uniform definition of an inhibitor.

Reference Values

Only orderable as a reflex. For more information see:

-ALBLD / Bleeding Diathesis Profile, Limited, Plasma

-ACBL / Bleeding Diathesis Profile, Comprehensive, Plasma

-APROL / Prolonged Clot Time Profile, Plasma

-2INHE / Factor II Inhibitor Evaluation, Plasma

-7INHE / Factor VII Inhibitor Evaluation, Plasma

-10INE / Factor X Inhibitor Evaluation, Plasma

-11INE / Factor XI Inhibitor Evaluation, Plasma

 

≤0.5 Bethesda Units

Interpretation

An interpretive report will be provided when testing is complete.

Cautions

No significant cautionary statements

Method Description

Undiluted patient plasma and serially diluted patient plasma are mixed with an equal volume of normal pooled plasma (NPP). The NPP supplies the factor against which the inhibitor is directed in a known concentration. The patient plasma mixtures, along with a control (Bethesda Pool) of diluted NPP are incubated at 37° C for 2 hours, after which factor activity is measured. The factor activity in the undiluted patient and its serial dilutions are compared to the factor activity recovered in the Bethesda Pool. These values are then used to calculate Bethesda units. One Bethesda unit is defined as the amount of antibody that will destroy 50% of the coagulation factor activity in 2 hours.( Owen CA Jr, Bowie EJW, Thompson JH Jr: Diagnosis of Bleeding Disorders. 2nd ed. Little, Brown and Company; 1975; Meijer P, Verbruggen HW, Spannagi M: Clotting factors and inhibitors: Assays and interpretation. In: Kottke-Marchant K, ed. Laboratory Hematology Practice. Wiley Blackwell Publishing; 2012:435-446)

Day(s) Performed

Monday through Friday

Report Available

2 to 5 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

85335

LOINC Code Information

Test ID Test Order Name Order LOINC Value
GBETH General Factor Bethesda Units, P 13591-3

 

Result ID Test Result Name Result LOINC Value
607434 General Factor Bethesda Units, P 13591-3